Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia

Background Streptococcus pneumoniae is a major causative agent in community-acquired pneumonia and sepsis. Overwhelming lung inflammation during pneumococcal pneumonia may hamper lung function. Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase (Btk), a key signaling protein controll...

Full description

Saved in:

Bibliographic Details
Published in:	Molecular medicine (Cambridge, Mass.) Vol. 25; no. 1; pp. 3 - 10
Main Authors:	de Porto, Alexander P., Liu, Zhe, de Beer, Regina, Florquin, Sandrine, de Boer, Onno J., Hendriks, Rudi W., van der Poll, Tom, de Vos, Alex F.
Format:	Journal Article
Language:	English
Published:	London BioMed Central 15.01.2019 Springer Nature B.V BMC
Subjects:	Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors Animals Anti-Bacterial Agents - therapeutic use Anti-Inflammatory Agents - therapeutic use Biomedical and Life Sciences Biomedicine Bronchoalveolar Lavage Fluid - cytology Bruton’s tyrosine kinase Ceftriaxone - therapeutic use Cytokines Experiments Flow cytometry Ibrutinib Inflammation Inhibitor drugs Kinases Lavage Lipopolysaccharides Lung - drug effects Lung - immunology Male Mice, Inbred C57BL Mice, Knockout Molecular Medicine Myeloid Cells - drug effects Myeloid Cells - immunology Pneumonia Pneumonia, Pneumococcal - drug therapy Pneumonia, Pneumococcal - immunology Protein Kinase Inhibitors - therapeutic use Pyrazoles - therapeutic use Pyrimidines - therapeutic use Research Article Sepsis Statistical analysis Streptococcus infections Streptococcus pneumoniae Teichoic Acids Tumor necrosis factor-TNF Netherlands Bruton’s tyrosine kinase Sepsis Pneumonia Ibrutinib Streptococcus pneumoniae
ISSN:	1076-1551, 1528-3658, 1528-3658
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!